ALCON INC (ALC): Financial results for Q2 2026
ALCON INC (ALC) furnished an SEC Form 6-K — earnings release. New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth • Second-quarter 2026 sales of $2.8 billion, up 8% on a reported basis, or up 7% constant currency 1 (cc), versus second-quarter 2025 • Returned $538 million to shareholders through divi
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest a short‑term bullish catalyst for the stock, though execution risk remains around product discontinuations.
Market read
Alcon's earnings exceed expectations and include a guidance upgrade, making the news highly relevant for traders focused on healthcare and medical‑device equities.
What to watch
Discontinuation of PowerVision IOL programs could pressure future pipeline growth.
New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth
Second-quarter net sales rose 8% reported and 7% constant currency, while core operating income increased 17% and core diluted EPS increased 11%. Reported operating income fell 96% and diluted EPS was $0.00 after a pre-tax, non-cash net charge of $402 million related to discontinuing the PowerVision programs.
Actuals vs. the company’s prior outlook
from its previous release| Metric | Guided | Reported | Verdict |
|---|---|---|---|
| Net sales growth vs. prior year (cc) | +5% to +7% | 7% constant currency | in line |
| Core operating margin change vs. prior year (cc) | +70 to +170 bps | increased 1.6 percentage points on a constant currency basis | n/a |
| Core diluted EPS growth vs. prior year (cc) | +10% to +13% | 9% on a constant currency basis | below |
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net salesother | $2,782 million | – | 8% reported; 7% constant currency |
| Net sales and other revenuesother | $2,823 million | – | – |
| Other revenuesother | $41 million | – | – |
| Cost of net salesother | $(1,130) million | – | 6% reported; 6% constant currency |
| Cost of other revenuesother | $(18) million | – | – |
| Gross profitother | $1,675 million | – | 21% reported; 20% constant currency |
| Gross marginother | 60.2% | – | – |
| Selling, general & administrationother | $(964) million | – | (11)% reported; (10)% constant currency |
| Research & developmentother | $(663) million | – | (171)% reported; (170)% constant currency |
| Other incomeother | $6 million | – | 20% reported; 8% constant currency |
| Other expenseother | $(43) million | – | (39)% reported; (33)% constant currency |
| Operating incomeother | $11 million | – | (96)% reported; (97)% constant currency |
| Operating marginother | 0.4% | – | decreased 9.2 percentage points on a reported basis and 9.3 percentage points on a constant currency basis |
| Core gross profitnon-GAAP | $1,799 million | – | 12% reported; 11% constant currency |
| Core gross marginnon-GAAP | 64.7% | – | – |
| Core operating incomenon-GAAP | $574 million | – | 17% reported; 16% constant currency |
| Core operating marginnon-GAAP | 20.6% | – | increased 1.5 percentage points on a reported basis and 1.6 percentage points on a constant currency basis |
| Interest expenseother | $(53) million | – | (4)% reported; (4)% constant currency |
| Other financial income & expenseother | — | – | (100)% reported; (108)% constant currency |
| Share of loss from associated companiesother | $(4) million | – | (300)% reported; (230)% constant currency |
| (Loss)/income before taxesother | $(46) million | – | nm |
| Taxesother | $46 million | – | nm |
| Net income attributable to shareholders of Alcon Inc.other | — | – | (100)% reported; (104)% constant currency |
| Diluted earnings per shareother | $0.00 | – | (100)% reported; (104)% constant currency |
| Core taxesnon-GAAP | $(107) million | – | (70)% reported; (73)% constant currency |
| Core tax ratenon-GAAP | 20.7% | – | – |
| Core net income attributable to shareholders of Alcon Inc.non-GAAP | $410 million | – | 8% reported; 7% constant currency |
| Core diluted earnings per sharenon-GAAP | $0.84 | – | 11% reported; 9% constant currency |
| EBITDAnon-GAAP | $800 million | – | – |
| First-half net salesother | $5,467 million | – | 9% reported; 7% constant currency |
| First-half operating incomeother | $303 million | – | (58)% reported; (61)% constant currency |
| First-half core operating incomenon-GAAP | $1,143 million | – | 14% reported; 11% constant currency |
| First-half diluted earnings per shareother | $0.39 | – | (63)% reported; (68)% constant currency |
| First-half core diluted earnings per sharenon-GAAP | $1.69 | – | 13% reported; 10% constant currency |
| First-half net cash flows from operating activitiesother | $928 million | – | – |
| First-half free cash flownon-GAAP | $693 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| SurgicalGrowth was supported by recent product launches. | $1,570 million | – | 8% reported; 7% constant currency |
| ImplantablesIOLs increased 2% constant currency, primarily driven by the strong performance of PanOptix Pro and reflecting competitive pressures, partially offset by lower sales in surgical glaucoma. | $466 million | – | 2% reported; 1% constant currency |
| ConsumablesGrowth was driven by procedural growth and price increases with continued softness in the cataract market. | $825 million | – | 6% reported; 5% constant currency |
| Equipment/otherGrowth was led by recent equipment launches, including the Unity platform. | $279 million | – | 26% reported; 25% constant currency |
| Vision CareGrowth reflected contributions from contact lenses and ocular health. | $1,212 million | – | 8% reported; 7% constant currency |
| Contact lensesGrowth reflects product innovation and price increases, partially offset by declines in legacy products. | $726 million | – | 5% reported; 5% constant currency |
| Ocular healthGrowth was led by the dry eye portfolio, including Tryptyr and Systane. | $486 million | – | 13% reported; 12% constant currency |
FY 2026 outlook
- Revenue+5% to +7% net sales growth vs. prior year (cc)
- Tax rateapproximately 20% core effective tax rate
- Note+90 to +190 bps core operating margin change vs. prior year (cc)
- Note +12% to +15% core diluted EPS growth vs. prior year (cc)
- NoteAggregated markets grow approximately 3% to 4%
- Noteapproximately $40 million to $90 million full-year tariff impact, net of mitigating actions and refunds
- Noteapproximately $60 million anticipated refund from the U.S. government in the third quarter of 2026
- NoteNon-operating expense for FY 2026 is expected to be between $200 and $220 million
- NoteCapital expenditures are expected to be mid-single digits as a percentage of sales
- NoteApproximately 488 million weighted-averaged diluted shares
Capital returns
- Returned $469 million to shareholders in the second quarter, including $174 million of dividends and $295 million of share repurchases.
- Returned $538 million to shareholders through dividends and share repurchases on a year-to-date basis through the second quarter.
- Approximately $1.2 billion remained of the previously announced $1.5 billion authorization as of June 30, 2026.
- The program is expected to be completed over a three-year period.
What drove it
- Recent launches, including UNITY, PanOptix Pro and TRYPTYR, were identified as growth drivers.
- Equipment/other sales grew 26% reported, led by recent equipment launches including the Unity platform.
- Ocular health sales grew 13% reported, led by dry eye products including Tryptyr and Systane.
- Manufacturing efficiencies and $15 million of other revenue from a licensee supported second-quarter core operating income.
- Price increases and procedural growth supported Consumables, while contact lenses benefited from product innovation and price increases.
Concerns
- Alcon discontinued the PowerVision programs after latest clinical study data showed persistent unpredictable post-surgical visual outcomes in a subset of patients.
- The discontinuation generated a pre-tax, non-cash net charge of $402 million and a post-tax charge of approximately $287 million.
- Reported operating margin declined to 0.4% from 9.6%, and reported diluted EPS was $0.00 versus $0.35.
- Consumables faced continued softness in the cataract market, while Implantables faced competitive pressures and lower surgical glaucoma sales.
- The outlook assumes a full-year tariff impact, net of mitigating actions and refunds, of approximately $40 million to $90 million, expected to pressure cost of net sales.
What to watch
- Execution of the Unity platform, PanOptix Pro, Tryptyr and other recent launches.
- Whether procedural growth and price increases offset continued softness in the cataract market and legacy-product declines in contact lenses.
- Delivery of the maintained +5% to +7% constant-currency net sales growth outlook.
- Effect of tariffs, the anticipated approximately $60 million U.S. government refund in the third quarter of 2026, and reinvestment of approximately two-thirds of that refund.
- Progress toward the increased core operating margin and core diluted EPS growth outlooks.
Balance sheet and cash flow
- Net cash flows from operating activities were $928 million for the first six months of 2026, compared to $889 million in the prior year period.
- Free cash flow was $693 million for the six months of 2026, compared to $681 million in the prior year period.
- Net cash flows used in investing activities were $(440) million for the six months ended June 30, 2026.
- Net cash flows used in financing activities were $(643) million for the six months ended June 30, 2026.
- Net change in cash and cash equivalents was $(172) million for the six months ended June 30, 2026.
- Cash and cash equivalents were $1,355 million at June 30, 2026, compared to $1,527 million at December 31, 2025.
- Total financial debt was $(4,719) million at June 30, 2026, compared to $(4,737) million at December 31, 2025.
- Net (debt) was $(3,248) million at June 30, 2026, compared to $(3,125) million at December 31, 2025.
Analysis
Alcon reported second-quarter net sales of $2,782 million, up 8% reported and 7% constant currency. Both operating segments grew 8% reported. Within Surgical, Equipment/other increased 26% on recent equipment launches including Unity, while Consumables grew 6% on procedural growth and pricing despite continued cataract-market softness. Vision Care growth was led by Ocular health, up 13% reported, as dry-eye products including Tryptyr and Systane gained traction.
Underlying profitability improved. Gross profit was $1,675 million and gross margin was 60.2%, compared with 53.9% in the prior-year period. Core operating income rose to $574 million from $491 million, and core operating margin improved to 20.6% from 19.1%. Manufacturing efficiencies and $15 million of other revenue from a licensee supported core results, while sales and marketing behind launches offset part of that benefit. Core diluted EPS increased to $0.84 from $0.76.
Reported profitability was dominated by the PowerVision decision. Alcon recorded a pre-tax, non-cash net charge of $402 million, post-tax of $287 million, after determining that the acquired IOL programs did not produce acceptable patient outcomes. Operating income consequently fell to $11 million from $247 million, operating margin declined to 0.4% from 9.6%, and diluted EPS was $0.00 versus $0.35. The company stated that the charge has no impact on cash position and does not change its previously communicated long-range financial objectives.
Cash generation remained positive in the first half, with $928 million of net cash flows from operating activities and $693 million of free cash flow. Alcon returned $469 million during the quarter through $174 million of dividends and $295 million of repurchases. Net debt was $(3,248) million at June 30, 2026. The company maintained its +5% to +7% constant-currency sales growth outlook while raising core operating margin expansion to +90 to +190 bps and core diluted EPS growth to +12% to +15%. Tariffs remain a cost pressure, with the company forecasting an approximately $40 million to $90 million full-year impact net of mitigating actions and refunds.
Management, verbatim
Our team delivered strong second-quarter results and executed well across the business.
David J. Endicott, Chief Executive Officer
UNITY, PanOptix Pro, TRYPTYR and other recent launches are driving growth and reinforcing the strength of our innovation engine.
David J. Endicott, Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter comparisons for all reported second-quarter metrics were not provided.
- Quarterly net cash flows from operating activities and quarterly free cash flow were not provided.
- Quarterly cash balance, debt balance and net debt change versus the prior-year quarter were not provided.
- Gross-margin guidance and operating-expense guidance were not provided.
- A reported IFRS tax rate for the second quarter was not provided.
- A separate previous-release outlook was not provided; the filing includes May and August 2026 outlook ranges in its current outlook table.
- The reported quarter contains no revenue or earnings guidance for a specific third-quarter period.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Alcon (ALC) filed a Form 6‑K reporting its Q2 2026 results, including sales growth, dividend returns, and updated guidance.
Ticker impact
Q2 2026 sales rose 8% to $2.8 bn and the company raised its full‑year guidance on margin and EPS.
Potential price increase of 3‑5% in the next trading session.
Revenue beat and higher guidance typically drive buying pressure; the market has not yet priced the new outlook.
Market effects
Eye‑care and medical‑device sector may see modest uplift as Alcon signals strong demand.
North American healthcare stocks could benefit from the earnings beat.
Limited to the medical‑device space; no broad market effect.
Counterpoint
If the market has already priced the guidance lift, the upside may be muted.
Key entities
- companyAlcon Inc.
Global leader in eye‑care products, listed on NYSE under ticker ALC.
- executiveDavid J. Endicott
Chief Executive Officer of Alcon, quoted on the earnings release.
